Holen Sie sich die Stockscreener-App
67.00
0.04%
0.0192
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$66.98
Offen:
$66.61
24-Stunden-Volumen:
371.81K
Relative Volume:
0.20
Marktkapitalisierung:
$8.19B
Einnahmen:
$18.47M
Nettoeinkommen (Verlust:
$-589.53M
KGV:
-12.74
EPS:
-5.26
Netto-Cashflow:
$-399.80M
1W Leistung:
+3.03%
1M Leistung:
+7.08%
6M Leistung:
+77.08%
1J Leistung:
+44.41%
1-Tages-Spanne:
$65.54
$67.20
1-Wochen-Bereich:
$64.58
$67.67
52-Wochen-Spanne:
$29.31
$70.98
Cytokinetics Inc Stock (CYTK) Company Profile
Firmenname
Cytokinetics Inc
Sektor
Branche
Telefon
(650) 624-3000
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
67.02 | 8.19B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 119.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.38 | 83.75B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
845.39 | 52.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
337.25 | 44.12B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
355.93 | 39.73B | 4.98B | 69.60M | 525.67M | 0.5198 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-12-18 | Hochstufung | Goldman | Neutral → Buy |
| 2025-07-30 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-04-24 | Eingeleitet | Barclays | Overweight |
| 2025-02-07 | Eingeleitet | Citigroup | Buy |
| 2025-01-22 | Eingeleitet | Stifel | Buy |
| 2024-11-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-13 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-07 | Eingeleitet | B. Riley Securities | Buy |
| 2023-08-15 | Eingeleitet | SVB Securities | Outperform |
| 2023-02-17 | Eingeleitet | BofA Securities | Neutral |
| 2022-12-23 | Bestätigt | Needham | Buy |
| 2022-12-20 | Eingeleitet | Truist | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-01-28 | Eingeleitet | Goldman | Buy |
| 2021-12-22 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2021-02-18 | Eingeleitet | Barclays | Overweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-29 | Eingeleitet | Goldman | Neutral |
| 2020-07-10 | Eingeleitet | Raymond James | Strong Buy |
| 2020-05-05 | Eingeleitet | Mizuho | Buy |
| 2020-04-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Bestätigt | Morgan Stanley | Overweight |
| 2017-11-22 | Herabstufung | Needham | Strong Buy → Buy |
| 2017-11-21 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-03-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-02-06 | Hochstufung | Needham | Buy → Strong Buy |
| 2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Bestätigt | Needham | Buy |
| 2015-11-10 | Bestätigt | FBR Capital | Outperform |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-07-24 | Bestätigt | MLV & Co | Buy |
| 2014-12-31 | Bestätigt | ROTH Capital | Buy |
| 2014-11-04 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-04-28 | Bestätigt | Needham | Buy |
Alle ansehen
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Cytokinetics Secures Triple Crown: EU Approval of MYQORZO Solidifies Global Reach in Cardiovascular Market - FinancialContent
Skandinaviska Enskilda Banken AB publ Boosts Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Cytokinetics Wins EU Approval for Cardiovascular Drug Myqorzo - Yahoo Finance
Truist Notes Operational Investments For Cytokinetics, Incorporated (CYTK) to Support Short-Term Growth - Finviz
Earnings Preview: Cytokinetics (CYTK) Q4 Earnings Expected to Decline - Finviz
Cytokinetics wins EC nod for Myqorzo - The Pharma Letter
Cytokinetics Reports EC Approval of Myqorzo for Obstructive Hypertrophic Cardiomyopathy - marketscreener.com
Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy - The Manila Times
Cytokinetics Receives European Commission Approval for MYQORZO® (aficamten) to Treat Obstructive Hypertrophic Cardiomyopathy; Launch Planned in Germany for Q2 2026 - Quiver Quantitative
Cytokinetics (CYTK) Expected to Announce Earnings on Tuesday - MarketBeat
Cytokinetics, Incorporated (CYTK) Stock Analysis: A 35.74% Potential Upside Fuels Investor Interest - DirectorsTalk Interviews
Does Cytokinetics Incorporated offer margin of safetyJuly 2025 Price Swings & Daily Growth Stock Investment Tips - mfd.ru
CYTOKINETICS INC (NASDAQ:CYTK) Shows Strong Technicals and High-Quality Breakout Setup - ChartMill
Will Cytokinetics Incorporated stock outperform Nasdaq index2025 Macro Impact & AI Driven Price Forecasts - mfd.ru
Cytokinetics (CYTK) Valuation Check After MYQORZO Approval And Renewed Analyst Bullishness - Yahoo Finance
Cytokinetics to Announce Fourth Quarter Results on February 24, 2026 - Bitget
Cytokinetics (CYTK) Is Up 5.2% After Aficamten Milestones And Probe News Has The Bull Case Changed? - Yahoo Finance
Cytokinetics, Incorporated (NASDAQ: CYTK) Long Term Investor Alert: Investigation of potential Wrongdoing - openPR.com
Analysts Are Bullish on Top Healthcare Stocks: Cytokinetics (CYTK), Boston Scientific (BSX) - The Globe and Mail
Cytokinetics announces recipients of its eighth annual communications grant program - marketscreener.com
Cytokinetics Announces Recipients Of Its Eighth Annual Communications Grant Program - TradingView
Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program - The Manila Times
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Aug Selloffs: Is Cytokinetics Incorporated a potential multi baggerJuly 2025 Setups & Weekly High Potential Alerts - baoquankhu1.vn
Bank Watch: Does Cytokinetics Incorporated offer margin of safetyJuly 2025 Momentum & Stepwise Trade Signal Implementation - baoquankhu1.vn
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Andrew Callos Sells 15,000 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Bank of America Securities Remains a Hold on Cytokinetics (CYTK) - The Globe and Mail
Surprises Report: Is Cytokinetics Incorporated stock a good pick for beginners2025 Support & Resistance & AI Enhanced Execution Alerts - baoquankhu1.vn
Cytokinetics stock maintains Buy rating at B.Riley amid strong CMI market - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect - ACCESS Newswire
Cytokinetics, Incorporated (CYTK): A Bull Case Theory - Finviz
Truist Financial Forecasts Strong Price Appreciation for Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Truist Raises Price Target on Cytokinetics to $92 From $84, Keeps Buy Rating - marketscreener.com
Truist Securities Raises Price Target for CYTK with Buy Rating | - GuruFocus
2026 Biotech Hot Picks: Top 7 Stocks to Watch | Truist Analysis - techi.com
Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech Play with a 41.55% Upside Potential - DirectorsTalk Interviews
Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 886 Shares - MarketBeat
New Highs: Whats the RSI of Cytokinetics Incorporated stockQuarterly Market Review & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Lisanti Capital Growth LLC Acquires New Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Sells 444,464 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Will Cytokinetics Incorporated outperform its industry peersShort Setup & Stock Portfolio Risk Management - mfd.ru
J. Safra Sarasin Holding AG Sells 43,723 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cardiac Myosin Inhibitor Now Available for Treating Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy - Diagnostic and Interventional Cardiology
Halozyme buys a biotech startup; Cytokinetics launches heart drug - BioPharma Dive
Cytokinetics (CYTK) Receives Overweight Rating from Barclays, PT Set at $87 | CYTK Stock News - GuruFocus
Cytokinetics (NASDAQ:CYTK) Coverage Initiated by Analysts at Barclays - MarketBeat
Cytokinetics, Olympic Medalist McLaughlin-Levrone team up for awareness for HCM - Yahoo Finance
CYTK: Cytokinetics Launches Myqorzo in the U.S. for Heart Condition - GuruFocus
Assessing Whether Cytokinetics (CYTK) Looks Undervalued After Recent Share Price Momentum - Yahoo Finance
Finanzdaten der Cytokinetics Inc-Aktie (CYTK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.40%
1.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):